Daily Medication Pearl: Prezista (Darunavir)

Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.

Medication Pearl of the Day: Prezista (Darunavir)

Indication: Prezista is an protease inhibitor indicated for the treatment of HIV-1 infection in patients aged 3 years and older.

Insights:

  • Dosing: Treatment-experienced and -naïve adult patients with no darunavir resistance-associated substitutions: 800 mg (2 400-mg tablets) taken with ritonavir 100 mg once daily and with food
  • Dosage forms: 100 mg/mL oral suspension-75 mg tablets, 150-mg tablets, 400-mg tablets, and 600-mg tablets
  • Adverse events: The most common clinical adverse drug reactions to Prezista/ritonavir (an incidence equal to greater than 5%) of at least moderate intensity (equal to or greater than grade 2) were abdominal pain, headaches, diarrhea, nausea, rash, and vomiting.
  • Mechanism of action: Darunavir is an HIV-1 antiviral drug.
  • Manufacturer: Janssen Pharmaceuticals

Source:

Prezista (darunavir) tablet label (fda.gov)